HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $8 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained an $8 price target.
June 26, 2023 | 12:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce reiterated a Buy rating on Unicycive Therapeutics and maintained an $8 price target.
The reiteration of the Buy rating and maintenance of the $8 price target by HC Wainwright & Co. analyst Ed Arce indicates a positive outlook for Unicycive Therapeutics. This could lead to increased investor confidence and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100